JPMorgan Starts MAP Pharmaceuticals (MAPP) at Overweight
Tweet
Share
E-mailGet Alerts MAPP Hot Sheet
Price: $21.40 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
JPMorgan initiates coverage on MAP Pharmaceuticals (NASDAQ: MAPP) with an Overweight. PT $23.00.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $13.44 yesterday.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $13.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
- H.C. Wainwright Starts Processa Pharmaceuticals (PCSA) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
